Christopher K. Rushton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christopher K. Rushton has a total of 232 co-authors. Here are the top co-authors by number of shared publications:
- Laura K. Hilton
BC Cancer, Vancouver, British Columbia, Canada
14 shared publications - Ryan David Morin
Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada
14 shared publications - Bruno M. Grande
Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada
12 shared publications - Aixiang Jiang
Centre for Lymphoid Cancer, BC Cancer, Vancouver, Canada
11 shared publications David W. Scott
11 shared publications- Jeffrey Tang
Department of Anesthesiology, Pharmacology & Therapeutics, The University of British Columbia, Vancouver, Canada
8 shared publications
Latest Publications
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from PRPS-ST: A Protocol-Agnostic Self-training Method for Gene Expression–Based Classification of Blood Cancers
Gene expression classifiers are gaining increasing popularity for stratifying tumors into subgroups with distinct biological features. A fundamental limitation shared by current classifiers is the requirement for comparable training and testing datasets. Here, we describe a self-training implementation of our probability ratio-based classification prediction score method (PRPS-ST), which facilitates the porting of existing classification models to other gene expression datasets. In comparison with gold standards, we demonstrate favorable performance of PRPS-ST in gene expression–based classification of diffuse large B-cell lymphoma (DLBCL) and B-lineage acute lymphoblastic leukemia (B-ALL) using a diverse variety of gene expression data types and preprocessing methods, including in classifications with a high degree of class imbalance. Tumors classified by our method were significantly enriched for prototypical genetic features of their respective subgroups. Interestingly, this included cases that were unclassifiable by established methods, implying the potential enhanced sensitivity of PRPS-ST.Significance:The adoption of binary classifiers such as cell of origin (COO) has been thwarted, in part, by the challenges imposed by batch effects and continual evolution of gene expression technologies. PRPS-ST resolves this by enabling classifiers to be ported across platforms while retaining high accuracy.This article is highlighted in the In This Issue feature, p. 215
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from PRPS-ST: A Protocol-Agnostic Self-training Method for Gene Expression–Based Classification of Blood Cancers
Gene expression classifiers are gaining increasing popularity for stratifying tumors into subgroups with distinct biological features. A fundamental limitation shared by current classifiers is the requirement for comparable training and testing datasets. Here, we describe a self-training implementation of our probability ratio-based classification prediction score method (PRPS-ST), which facilitates the porting of existing classification models to other gene expression datasets. In comparison with gold standards, we demonstrate favorable performance of PRPS-ST in gene expression–based classification of diffuse large B-cell lymphoma (DLBCL) and B-lineage acute lymphoblastic leukemia (B-ALL) using a diverse variety of gene expression data types and preprocessing methods, including in classifications with a high degree of class imbalance. Tumors classified by our method were significantly enriched for prototypical genetic features of their respective subgroups. Interestingly, this included cases that were unclassifiable by established methods, implying the potential enhanced sensitivity of PRPS-ST.Significance:The adoption of binary classifiers such as cell of origin (COO) has been thwarted, in part, by the challenges imposed by batch effects and continual evolution of gene expression technologies. PRPS-ST resolves this by enabling classifiers to be ported across platforms while retaining high accuracy.This article is highlighted in the In This Issue feature, p. 215
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from PRPS-ST: A Protocol-Agnostic Self-training Method for Gene Expression–Based Classification of Blood Cancers
Gene expression classifiers are gaining increasing popularity for stratifying tumors into subgroups with distinct biological features. A fundamental limitation shared by current classifiers is the requirement for comparable training and testing datasets. Here, we describe a self-training implementation of our probability ratio-based classification prediction score method (PRPS-ST), which facilitates the porting of existing classification models to other gene expression datasets. In comparison with gold standards, we demonstrate favorable performance of PRPS-ST in gene expression–based classification of diffuse large B-cell lymphoma (DLBCL) and B-lineage acute lymphoblastic leukemia (B-ALL) using a diverse variety of gene expression data types and preprocessing methods, including in classifications with a high degree of class imbalance. Tumors classified by our method were significantly enriched for prototypical genetic features of their respective subgroups. Interestingly, this included cases that were unclassifiable by established methods, implying the potential enhanced sensitivity of PRPS-ST.Significance:The adoption of binary classifiers such as cell of origin (COO) has been thwarted, in part, by the challenges imposed by batch effects and continual evolution of gene expression technologies. PRPS-ST resolves this by enabling classifiers to be ported across platforms while retaining high accuracy.This article is highlighted in the In This Issue feature, p. 215
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from PRPS-ST: A Protocol-Agnostic Self-training Method for Gene Expression–Based Classification of Blood Cancers
Gene expression classifiers are gaining increasing popularity for stratifying tumors into subgroups with distinct biological features. A fundamental limitation shared by current classifiers is the requirement for comparable training and testing datasets. Here, we describe a self-training implementation of our probability ratio-based classification prediction score method (PRPS-ST), which facilitates the porting of existing classification models to other gene expression datasets. In comparison with gold standards, we demonstrate favorable performance of PRPS-ST in gene expression–based classification of diffuse large B-cell lymphoma (DLBCL) and B-lineage acute lymphoblastic leukemia (B-ALL) using a diverse variety of gene expression data types and preprocessing methods, including in classifications with a high degree of class imbalance. Tumors classified by our method were significantly enriched for prototypical genetic features of their respective subgroups. Interestingly, this included cases that were unclassifiable by established methods, implying the potential enhanced sensitivity of PRPS-ST.Significance:The adoption of binary classifiers such as cell of origin (COO) has been thwarted, in part, by the challenges imposed by batch effects and continual evolution of gene expression technologies. PRPS-ST resolves this by enabling classifiers to be ported across platforms while retaining high accuracy.This article is highlighted in the In This Issue feature, p. 215
- Open Access
Relapse timing is associated with distinct evolutionary dynamics in DLBCL
Diffuse large B-cell lymphoma (DLBCL) is cured in over 60% of patients, but outcomes are poor for patients with relapsed or refractory disease (rrDLBCL). Here, we performed whole genome/exome sequencing (WGS/WES) on tumors from 73 serially-biopsied patients with rrDLBCL. Based on the observation that outcomes to salvage therapy/autologous stem cell transplantation are related to time-to-relapse, we stratified patients into groups according to relapse timing to explore the relationship to genetic divergence and sensitivity to salvage immunochemotherapy. The degree of mutational divergence increased with time between biopsies, yet tumor pairs were mostly concordant for cell-of-origin, oncogene rearrangement status and genetics-based subgroup. In patients with highly divergent tumors, several genes acquired exclusive mutations independently in each tumor, which, along with concordance of genetics-based subgroups, suggests that the earliest mutations in a shared precursor cell constrain tumor evolution. These results suggest that late relapses commonly represent genetically distinct and chemotherapy-naïve disease.
Open AccessRelapse timing is associated with distinct evolutionary dynamics in DLBCL
Diffuse large B-cell lymphoma (DLBCL) is cured in over 60% of patients, but outcomes are poor for patients with relapsed or refractory disease (rrDLBCL). Here, we performed whole genome/exome sequencing (WGS/WES) on tumors from 73 serially-biopsied patients with rrDLBCL. Based on the observation that outcomes to salvage therapy/autologous stem cell transplantation are related to time-to-relapse, we stratified patients into groups according to relapse timing to explore the relationship to genetic divergence and sensitivity to salvage immunochemotherapy. The degree of mutational divergence increased with time between biopsies, yet tumor pairs were mostly concordant for cell-of-origin, oncogene rearrangement status and genetics-based subgroup. In patients with highly divergent tumors, several genes acquired exclusive mutations independently in each tumor, which, along with concordance of genetics-based subgroups, suggests that the earliest mutations in a shared precursor cell constrain tumor evolution. These results suggest that late relapses commonly represent genetically distinct and chemotherapy-naïve disease.
- Open Access
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 9259-9260
Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL
Introduction Patients with diffuse large B-cell lymphoma (DLBCL) are generally treated in the frontline setting with a standard immunochemotherapy regimen (R-CH
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 9259-9260
Open AccessRecurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL
Introduction Patients with diffuse large B-cell lymphoma (DLBCL) are generally treated in the frontline setting with a standard immunochemotherapy regimen (R-CH
- Open Access
- 1 October 2021
- Published by Elsevier in Cell Reports
- Vol. 37 (2) , 109817
Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms
- 1 October 2021
- Published by Elsevier in Cell Reports
- Vol. 37 (2) , 109817
Open AccessProteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms
- 29 July 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (15) , 2945-2957
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment
Fc γ receptor IIB (FcγRIIB) is an inhibitory molecule capable of reducing antibody immunotherapy efficacy. We hypothesized its expression could confer resistance in patients with diffuse large B-cell lymphoma (DLBCL) treated with anti-CD20 monoclonal antibody (mAb) chemoimmunotherapy, with outcomes varying depending on mAb (rituximab [R]/obinutuzumab [G]) because of different mechanisms of action. We evaluated correlates between FCGR2B messenger RNA and/or FcγRIIB protein expression and outcomes in 3 de novo DLBCL discovery cohorts treated with R plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reported by Arthur, Schmitz, and Reddy, and R-CHOP/G-CHOP-treated patients in the GOYA trial (NCT01287741). In the discovery cohorts, higher FCGR2B expression was associated with significantly shorter progression-free survival (PFS; Arthur: hazard ratio [HR], 1.09; 95% confidence interval [CI], 1.01-1.19; P = .0360; Schmitz: HR, 1.13; 95% CI, 1.02-1.26; P = .0243). Similar results were observed in GOYA with R-CHOP (HR, 1.26; 95% CI, 1.00-1.58; P = .0455), but not G-CHOP (HR, 0.91; 95% CI, 0.69-1.20; P = .50). A nonsignificant trend that high FCGR2B expression favored G-CHOP over R-CHOP was observed (HR, 0.67; 95% CI, 0.44-1.02; P = .0622); however, low FCGR2B expression favored R-CHOP (HR, 1.58; 95% CI, 1.00-2.50; P = .0503). In Arthur and GOYA, FCGR2B expression was associated with tumor FcγRIIB expression; correlating with shorter PFS for R-CHOP (HR, 2.17; 95% CI, 1.04-4.50; P = .0378), but not G-CHOP (HR, 1.37; 95% CI, 0.66-2.87; P = .3997). This effect was independent of established prognostic biomarkers. High FcγRIIB/FCGR2B expression has prognostic value in R-treated patients with DLBCL and may confer differential responsiveness to R-CHOP/G-CHOP.
- 29 July 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (15) , 2945-2957
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment
Fc γ receptor IIB (FcγRIIB) is an inhibitory molecule capable of reducing antibody immunotherapy efficacy. We hypothesized its expression could confer resistance in patients with diffuse large B-cell lymphoma (DLBCL) treated with anti-CD20 monoclonal antibody (mAb) chemoimmunotherapy, with outcomes varying depending on mAb (rituximab [R]/obinutuzumab [G]) because of different mechanisms of action. We evaluated correlates between FCGR2B messenger RNA and/or FcγRIIB protein expression and outcomes in 3 de novo DLBCL discovery cohorts treated with R plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reported by Arthur, Schmitz, and Reddy, and R-CHOP/G-CHOP-treated patients in the GOYA trial (NCT01287741). In the discovery cohorts, higher FCGR2B expression was associated with significantly shorter progression-free survival (PFS; Arthur: hazard ratio [HR], 1.09; 95% confidence interval [CI], 1.01-1.19; P = .0360; Schmitz: HR, 1.13; 95% CI, 1.02-1.26; P = .0243). Similar results were observed in GOYA with R-CHOP (HR, 1.26; 95% CI, 1.00-1.58; P = .0455), but not G-CHOP (HR, 0.91; 95% CI, 0.69-1.20; P = .50). A nonsignificant trend that high FCGR2B expression favored G-CHOP over R-CHOP was observed (HR, 0.67; 95% CI, 0.44-1.02; P = .0622); however, low FCGR2B expression favored R-CHOP (HR, 1.58; 95% CI, 1.00-2.50; P = .0503). In Arthur and GOYA, FCGR2B expression was associated with tumor FcγRIIB expression; correlating with shorter PFS for R-CHOP (HR, 2.17; 95% CI, 1.04-4.50; P = .0378), but not G-CHOP (HR, 1.37; 95% CI, 0.66-2.87; P = .3997). This effect was independent of established prognostic biomarkers. High FcγRIIB/FCGR2B expression has prognostic value in R-treated patients with DLBCL and may confer differential responsiveness to R-CHOP/G-CHOP.